| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | YM-155 | CTRPv2 | pan-cancer | AAC | -0.0034 | 0.9 |
| mRNA | BRD-K33199242 | CTRPv2 | pan-cancer | AAC | -0.0034 | 0.9 |
| mRNA | PI-103 | CTRPv2 | pan-cancer | AAC | -0.003 | 0.9 |
| mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | 0.0031 | 0.9 |
| mRNA | PRIMA-1-Met | CTRPv2 | pan-cancer | AAC | 0.0044 | 0.9 |
| mRNA | BRD-K14844214 | CTRPv2 | pan-cancer | AAC | -0.0032 | 0.9 |
| mRNA | FK866 | CTRPv2 | pan-cancer | AAC | -0.0031 | 0.9 |
| mRNA | BRD-K51831558 | CTRPv2 | pan-cancer | AAC | -0.0044 | 0.9 |
| mRNA | lenalidomide | GDSC1000 | pan-cancer | AAC | -0.0029 | 0.9 |
| mRNA | KIN001-244 | GDSC1000 | pan-cancer | AAC | 0.0025 | 0.9 |